Literature DB >> 12777081

Postoperative management of patients after stereotactic biopsy: results of a survey of the AANS/CNS section on tumors and a single institution study.

Ronald E Warnick1, Lynn M Longmore, Christian A Paul, Laurie A Bode.   

Abstract

As little consensus exists on the postoperative care of patients undergoing stereotactic biopsy, we sought to establish a new algorithm for their postoperative management. First, we surveyed active members of the AANS/CNS Section on Tumors to determine national practice patterns for patients after stereotactic biopsy. Second, we retrospectively reviewed 84 consecutive stereotactic biopsy procedures at our institution to assess the potential benefit of routine computed tomography (CT) scanning and intensive care unit (ICU) monitoring. Finally, we prospectively applied this new algorithm in 54 patients to assess its validity. Of 629 surgeons, 263 (42%) responded; they were experienced neurosurgeons (mean 15 years in practice) who performed more than 10 stereotactic biopsies per year. Most surgeons (59%) routinely ordered postoperative CT scans, and the remainder ordered scans based on specific indications. Patients were transferred from the recovery room to a special care unit (47%), regular room (47%), or home (6%). In our retrospective review, 81 patients underwent 84 stereotactic biopsy procedures; 79 underwent postoperative CT scanning and all 81 were monitored overnight in the ICU. Among five (6%) patients who experienced intraoperative hemorrhage, two (2%) underwent craniotomy to control arterial bleeding. Three (4%) patients developed new neurological deficits, which occurred within 2 h of surgery. In both groups, CT scans were helpful in excluding hemorrhage that would require re-operation. In the remaining patients (90%), findings on routine postoperative CT did not alter patient management and ICU monitoring appeared unnecessary because neurological complications occurred within 2 h postoperatively. We confirmed these results in the prospective study of 54 patients undergoing stereotactic biopsy without routine postoperative CT scanning or ICU monitoring. In contrast with national practice patterns reported, we recommend that CT scanning and ICU monitoring be reserved for patients who have intraoperative hemorrhage or new deficits after surgery. All other patients can be monitored for 2 h in the recovery room and transferred to a regular hospital room without a postoperative CT scan.

Entities:  

Mesh:

Year:  2003        PMID: 12777081     DOI: 10.1023/a:1023315206736

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  16 in total

1.  Clinical and economic consequences of early discharge of patients following supratentorial stereotactic brain biopsy.

Authors:  W Kaakaji; G H Barnett; D Bernhard; A Warbel; K Valaitis; S Stamp
Journal:  J Neurosurg       Date:  2001-06       Impact factor: 5.115

Review 2.  Role of stereotaxic biopsy in the management of patients with intracranial lesions.

Authors:  D E Bullard
Journal:  Neurol Clin       Date:  1985-11       Impact factor: 3.806

3.  Computed imaging stereotaxy: experience and perspective related to 500 procedures applied to brain masses.

Authors:  M L Apuzzo; P T Chandrasoma; D Cohen; C S Zee; V Zelman
Journal:  Neurosurgery       Date:  1987-06       Impact factor: 4.654

4.  CT stereotactic biopsy for optimizing the therapy of intracranial processes.

Authors:  F Mundinger
Journal:  Acta Neurochir Suppl (Wien)       Date:  1985

5.  Stereotactic surgery for mass lesions of the midbrain and pons.

Authors:  R J Coffey; L D Lunsford
Journal:  Neurosurgery       Date:  1985-07       Impact factor: 4.654

6.  Complications of CT-guided stereotactic biopsy of intra-axial brain lesions.

Authors:  M Bernstein; A G Parrent
Journal:  J Neurosurg       Date:  1994-08       Impact factor: 5.115

7.  Stereotactic biopsy of brain tumors.

Authors:  C B Ostertag; H D Mennel; M Kiessling
Journal:  Surg Neurol       Date:  1980-10

8.  Incidence of silent hemorrhage and delayed deterioration after stereotactic brain biopsy.

Authors:  A V Kulkarni; A Guha; A Lozano; M Bernstein
Journal:  J Neurosurg       Date:  1998-07       Impact factor: 5.115

9.  Nondiagnostic CT-guided stereotactic biopsies in a series of 407 cases: influence of CT morphology and operator experience.

Authors:  A Ranjan; V Rajshekhar; T Joseph; M J Chandy; S M Chandi
Journal:  J Neurosurg       Date:  1993-12       Impact factor: 5.115

10.  Intracranial tumor biopsy--CT-guided stereotactic surgery.

Authors:  M Poza; M A Perez-Espejo; J F Martinez-Lage; J A Esteban; V Climent; J Sola
Journal:  Appl Neurophysiol       Date:  1985
View more
  6 in total

1.  History of the AANS/CNS joint section on tumors and preface to the 20th anniversary Journal of Neuro-Oncology Special Issue.

Authors:  Fred G Barker; Mark E Linskey
Journal:  J Neurooncol       Date:  2004 Aug-Sep       Impact factor: 4.130

2.  Symptomatic intracranial hemorrhages and frame-based stereotactic brain biopsy.

Authors:  Monica Lara-Almunia; Javier Hernandez-Vicente
Journal:  Surg Neurol Int       Date:  2020-08-01

3.  Tubular brain tumor biopsy improves diagnostic yield for subcortical lesions.

Authors:  Evan D Bander; Samuel H Jones; David Pisapia; Rajiv Magge; Howard Fine; Theodore H Schwartz; Rohan Ramakrishna
Journal:  J Neurooncol       Date:  2018-11-16       Impact factor: 4.130

4.  Management strategies after nondiagnostic results with frameless stereotactic needle biopsy: Retrospective review of 28 patients.

Authors:  Ellen L Air; Ronald E Warnick; Christopher M McPherson
Journal:  Surg Neurol Int       Date:  2012-10-31

5.  Outpatient stereotactic brain biopsies.

Authors:  Bertrand Mathon; Pauline Marijon; Maximilien Riche; Vincent Degos; Alexandre Carpentier
Journal:  Neurosurg Rev       Date:  2021-06-23       Impact factor: 2.800

6.  Risk factors for adverse events occurring after recovery from stereotactic brain biopsy in dogs with primary intracranial neoplasia.

Authors:  Richard L Shinn; Yukitaka Kani; Fang-Chi Hsu; John H Rossmeisl
Journal:  J Vet Intern Med       Date:  2020-09-14       Impact factor: 3.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.